Literature DB >> 20228081

Extracellular concentrations of fosfomycin in lung tissue of septic patients.

Veronika Matzi1, Jörg Lindenmann, Christian Porubsky, Sylvia A Kugler, Alfred Maier, Peter Dittrich, Freyja M Smolle-Jüttner, Christian Joukhadar.   

Abstract

OBJECTIVES: The present investigation explored the ability of fosfomycin to penetrate lung tissue of septic patients by utilizing the microdialysis technique.
METHODS: After microdialysis probe insertion into healthy and infected lung tissue, a single intravenous dose of 4 g of fosfomycin was administered.
RESULTS: The mean C(max), T(max), AUC(0-4) and AUC(0-infinity) for healthy lung were 131.6 +/- 110.6 mg/L, 1.1 +/- 0.4 h, 242.4 +/- 101.6 mgxh/L and 367.6 +/- 111.9 mgxh/L, respectively. The corresponding values for infected lung were 107.5 +/- 60.2 mg/L, 1.4 +/- 0.5 h, 203.5 +/- 118.4 mgxh/L and 315.1 +/- 151.2 mgxh/L. The half-life of fosfomycin ranged from 2.2 to 2.7 h between compartments. The magnitude of lung tissue penetration, as determined by the ratios of the AUC(0-infinity) for lung to the AUC(0-infinity) for plasma, was 0.63 +/- 0.31 and 0.53 +/- 0.31 for healthy and infected lung, respectively.
CONCLUSIONS: We conclude that fosfomycin achieves antimicrobially effective concentrations in infected lung tissue.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228081     DOI: 10.1093/jac/dkq070

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  23 in total

Review 1.  Fosfomycin: Resurgence of an old companion.

Authors:  Sangeeta Sastry; Yohei Doi
Journal:  J Infect Chemother       Date:  2016-02-28       Impact factor: 2.211

Review 2.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

Review 3.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 4.  A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.

Authors:  Friederike Traunmüller; Martin Popovic; Karl-Heinz Konz; Patrick Vavken; Andreas Leithner; Christian Joukhadar
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

Review 5.  Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.

Authors:  David van Duin; Keith S Kaye; Elizabeth A Neuner; Robert A Bonomo
Journal:  Diagn Microbiol Infect Dis       Date:  2013-01-03       Impact factor: 2.803

6.  Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Authors:  T Tängdén; R A Hickman; P Forsberg; P Lagerbäck; C G Giske; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

7.  Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.

Authors:  G Martín-Gutiérrez; F Docobo-Pérez; J Rodriguez-Beltrán; J M Rodríguez-Martínez; J Aznar; A Pascual; J Blázquez
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  Fosfomycin.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; George Samonis; Konstantinos Z Vardakas
Journal:  Clin Microbiol Rev       Date:  2016-04       Impact factor: 26.132

9.  Current clinical use of intravenous fosfomycin in ICU patients in two European countries.

Authors:  C Putensen; B Ellger; S G Sakka; A Weyland; K Schmidt; M Zoller; N Weiler; D Kindgen-Milles; U Jaschinski; J Weile; S Lindau; M Kieninger; A Faltlhauser; N Jung; P Teschendorf; M Adamzik; M Gründling; T Wahlers; H Gerlach; F-A Litty
Journal:  Infection       Date:  2019-06-12       Impact factor: 3.553

Review 10.  'Old' antibiotics for emerging multidrug-resistant bacteria.

Authors:  Phillip J Bergen; Cornelia B Landersdorfer; Hee Ji Lee; Jian Li; Roger L Nation
Journal:  Curr Opin Infect Dis       Date:  2012-12       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.